A phase IV, open-label assessment of the treatment of actinic keratoses with diclofenac sodium 3% topical gel

被引：1
|
作者：
Rigel, DS
Swanson, N
Wolf, J
Smith, S
机构：
[1] NYU, Med Ctr, New York, NY 10016 USA
[2] Oregon Hlth Sci Univ, Portland, OR 97201 USA
[3] Baylor Coll Med, Houston, TX 77030 USA
来源：
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY | 2004年 / 50卷 / 03期
关键词：
D O I：
10.1016/j.jaad.2003.10.421
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
P479
引用
收藏
页码：P124 / P124
页数：1
相关论文
共 50 条
  • [21] Evidence for field cancerisation treatment of actinic keratoses with topical diclofenac in hyaluronic acid
    Martina Ulrich
    Giovanni Pellacani
    Carlos Ferrandiz
    John T. Lear
    European Journal of Dermatology, 2014, 24 : 158 - 167
  • [22] An open-label 18-month study of fluorouracil cream 0.5% for the treatment of actinic keratoses
    Stough, Dow
    Davis, Steven A.
    Bucko, Alicia
    Rafal, Elyse
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2008, 58 (02) : AB102 - AB102
  • [23] Topical treatment of actinic keratoses with 3.0% diclofcnac in 2.5% hyaluronan gel
    Rivers, JK
    Arlette, J
    Shear, N
    Guenther, L
    Carey, W
    Poulin, Y
    BRITISH JOURNAL OF DERMATOLOGY, 2002, 146 (01) : 94 - 100
  • [24] Cold atmospheric plasma versus diclofenac 3% gel in patients with actinic keratoses
    Koch, F.
    Salva, K.
    Wirtz, M.
    Hadaschik, E.
    Varaljai, R.
    Schadendorf, D.
    Kehrmann, J.
    Roesch, A.
    EXPERIMENTAL DERMATOLOGY, 2022, 31 (02) : E24 - E24
  • [25] A Single-Arm, Open-Label, Phase IV Study to Evaluate the Efficacy of a Topical Formulation for Hyperkeratotic Actinic Keratosis Lesions
    De Padova, Maria Pia
    Marzani, Barbara
    Pinto, Daniela
    Rinaldi, Fabio
    DERMATOLOGY AND THERAPY, 2018, 8 (03) : 455 - 462
  • [26] A Single-Arm, Open-Label, Phase IV Study to Evaluate the Efficacy of a Topical Formulation for Hyperkeratotic Actinic Keratosis Lesions
    Maria Pia De Padova
    Barbara Marzani
    Daniela Pinto
    Fabio Rinaldi
    Dermatology and Therapy, 2018, 8 : 455 - 462
  • [27] Diclofenac sodium 3% gel as a potential treatment for disseminated superficial actinic porokeratosis
    Marks, S.
    Varma, R.
    Cantrell, W.
    Chen, S. C.
    Gold, M.
    Muellenhoff, M.
    Elewski, B.
    JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2009, 23 (01) : 42 - 45
  • [28] Diclofenac sodium 3% gel as a potential treatment for disseminated superficial actinic porokeratosis
    Varma, Rajat
    Cantrell, Wendy
    Elewski, Boni
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2008, 58 (02) : AB33 - AB33
  • [29] Topical 3.0% diclofenac in 2.5% hyaluronic acid gel induces regression of cancerous transformation in actinic keratoses
    Dirschka, T.
    Bierhoff, E.
    Pflugfelder, A.
    Garbe, C.
    JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2010, 24 (03) : 258 - 263
  • [30] Darier's disease: treatment with topical sodium diclofenac 3% gel
    de Campos, Marcella Oliveira Menezes Quitete
    de Figueiredo, Giovanna Abrantes Pimenta
    Evangelista, Allyson Capobiango
    Bauk, Alexander Richard
    ANAIS BRASILEIROS DE DERMATOLOGIA, 2023, 98 (06) : 882 - 884
12345